DocWire News Editors

DocwireNews

Results from the phase II IDIOME trial suggest that ivosidenib, a small-molecule mutant IDH1 inhibitor, showed good tolerability and significant efficacy in the treatment of three separate cohorts of patients with IDH1-mutated myelodysplastic syndrome (MDS). The findings were presented at the 2021 ASH Annual Meeting.During her presentation, the study&rsquo;s lead author Marie Sebert, MD, PhD, noted that &ldquo;ivosidenib was particularly effective in treatment-na&iuml;ve, higher-risk MDS patients with IDH1 mutations,&rdquo; with a response rate of 91%.The researchers administered continuous 28-day cycles of ivosidenib 500 mg orally once-daily to the following cohorts:<ul>
<li>patients with higher-risk MDS that previously failed treatment on azacitidine (cohort A, n=29)</li>
<li>patients with untreated higher-risk MDS without life-threatening cytopenias (cohort B, n=29)</li>
<li>patients with lower-risk MDS that previously failed on erythropoietin (cohort C, n=10)</li>
</ul>The primary endpoint was overall response rate (ORR) at three and six months, assessed via complete remission (CR), partial remission (PR), and stable disease with hematologic improvement (HI), as defined by the International Working Group (IWG) 2006. Secondary outcomes included safety, duration of response, event-free survival (EFS), and overall survival (OS). Treatment with azacitidine was added to one non-responding patient in cohort B after three cycles, with no additional response.At data cutoff, the ORR was 69% with 18 responses including 12 CR, one PR, and five HI. Seventeen of the 18 patients achieved their response after three cycles. The median response duration was 7.4 months. In the whole cohort, the median OS was 14 months. Twelve patients had disease progression and 11 patients died, mostly due to relapse or progression.Five serious treatment-related adverse events were reported, four of which were differentiation syndrome. One patient had febrile neutropenia related to ivosidenib treatment that was resolved without issue.Though the preliminary results were encouraging, Dr. Sebert acknowledged that their findings need to be confirmed in larger patient populations. The article noted that the IDIOME study is ongoing, and molecular monitoring results of IDH1 mutations will be published in the future.

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Latest News

Evaluating Ivosidenib in Patients with IDH1-Mutated Myelodysplastic Syndrome

ASH Annual Meeting and Exposition 2021

Results from the phase II IDIOME trial suggest that ivosidenib, a small-molecule mutant IDH1 inhibitor, showed good tolerability and significant efficacy in the treatment of ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe